HER2 (Phospho_Tyr1248) Antibody
- Known as:
- HER2 (Phospho_Tyr1248) Antibody
- Catalog number:
- E011079-1
- Product Quantity:
- 50ug
- Category:
- Antibodies
- Supplier:
- EnoGene
- Gene target:
- HER2 (Phospho_Tyr1248) Antibody
Related genes to: HER2 (Phospho_Tyr1248) Antibody
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 (Phospho_Tyr1248) Antibody
Related articles to: HER2 (Phospho_Tyr1248) Antibody
- Ductal carcinoma in situ (DCIS) is a preinvasive form of breast cancer. Current treatment consists of surgery, radiation, and often systemic therapy exposing patients to unnecessary health risks. Vaccines targeting DCIS may be a way to intercept preinvasive lesions and prevent the development of invasive breast cancer. - Source: PubMed
Publication date: 2026/05/04
Stanton Sasha ECecil Denise LBailey Howard HLiu YingGwin William RColveler Andrew LLiao John BWisinski Kari BBarroilhet LisaKim KyungMannHavighurst Thomas CDeShong KatinaTwaroski KyleighChilds Jennifer SDimond EileenWojtowicz MargaretHeckman-Stoddard Brandy MDisis Mary L - Premenopausal patients with node-positive, hormone receptor-positive, early breast cancer derive benefit from extended endocrine therapy (EET) following 5 years of luteinizing hormone-releasing hormone (LHRH) agonist-based treatment. The benefit of EET may differ according to surrogate breast cancer subtypes in postmenopausal patients. - Source: PubMed
Publication date: 2026/05/01
Valenza CarmineZheng YueMilano MonicaBerton Giachetti Pier Paolo MariaTrapani DarioGiordano ElisaGuidi LorenzoBoldrini LauraCastellano GraziaKatrini JalissaMalagutti BiancaAntonarelli GabrieleEtessami Julian DBianco NadiaConforti FabioKirkner Gregory JSangalli ClaudiaDibble Kate EFusco NicolaColleoni MarcoRegan Meredith MMunzone ElisabettaCurigliano GiuseppePartridge Ann H - Human epidermal growth factor receptor-2 (HER2) alterations, including activating mutations and gene amplification, are emerging therapeutic targets in several solid tumors. Trastuzumab-deruxtecan (T-DXd), a HER2-directed antibody-drug conjugate (ADC), has demonstrated antitumor activity across multiple HER2-altered cancers. However, complete metabolic responses (CMRs) remain uncommon, particularly when assessed by 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography-computed tomography (FDG-PET/CT). - Source: PubMed
Publication date: 2026/04/17
Le Meur ColineLe Roux Pierre-YvesAlemany PierreChauvelot FrédéricPradier OlivierNiel ClémenceBellange AlexChouaid ChristosMassard ChristopheAmrane Karim - : Precise intracellular delivery of chemotherapeutics remains a major challenge in HER2-positive breast cancer, where intratumoral heterogeneity and limited tissue penetration constrain efficacy. A key contributor is the tumor-restricted epidermal growth factor receptor variant III (EGFRvIII), a constitutively active, ligand-independent mutant generated by deletion of exons 2-7. Although classically associated with glioblastoma, lung (NSCLC), head/neck, and prostate cancers, EGFRvIII is also present in subsets of HER2-positive breast cancers, where low-abundance subclones drive aggressive phenotypes and attenuate therapeutic responses. HER2-EGFRvIII co-expression amplifies oncogenic signaling, supported by frequent co-expression in ErbB2-positive primary tumors and metastases, and by sustained receptor phosphorylation in the absence of EGFR gene amplification, depicting EGFRvIII as a compelling therapeutic target. : We evaluated the shark-derived single-domain antibody vNAR R426 as a modular theranostic platform for receptor-mediated cisplatin delivery. Conjugation to cisplatin and fluorescein enabled simultaneous intracellular drug transport and immunofluorescence-based detection in EGFRvIII-positive SKBR3 cells and 3D spheroids. The compact vNAR-based immunoconjugates support efficient receptor recognition, internalization, and intracellular trafficking, features rarely achieved by conventional IgG antibodies. : vNAR elicited robust, receptor-mediated cytotoxicity, achieving an IC of 2.68 µM-approximately 50-fold lower than that of free cisplatin-while unconjugated vNAR maintained scaffold biocompatibility. In three-dimensional spheroid models, the theranostic vNAR (vNAR) exhibited deep and uniform penetration throughout tumor-like architectures, with immunofluorescence intensity closely correlating with regions of intracellular drug delivery and the initiation of cytotoxic responses. Notably, cisplatin conjugation did not impair tissue diffusion or receptor engagement, facilitating effective payload delivery to both peripheral and central cell populations. : By integrating tumor-restricted targeting and efficient intracellular drug delivery within a modular single-domain scaffold, vNAR R426 represents a next-generation theranostic platform capable of addressing intratumoral heterogeneity. This approach combines potent cytotoxic activity with immunofluorescence-based detection, thereby advancing the rational design of precision therapeutics for HER2-positive breast cancer. - Source: PubMed
Publication date: 2026/04/17
Alfonseca-Ladrón de Guevara Andrea CManzanares-Guzmán AlejandroBadillo-Mata Jessica ABurciaga-Flores MirnaLugo-Fabres Pavel HCamacho-Villegas Tanya A - HER2-low breast cancer, also known as IHC 1+ or IHC 2+ without ERBB2 amplification, is a new concept in the biology of breast cancer that has removed the binary classification of HER2-positive or HER2-negative breast cancer. The recent introduction of antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd), has improved therapeutic outcomes for HER2-low breast cancer by demonstrating high efficacy in HER2-low tumors through efficient payload delivery. However, differences in ADC efficacy exist among HER2-low breast cancer patients, with tumor cells showing resistance to ADCs. Recent research indicates that the tumor microenvironment (TME) plays a critical role in determining the efficacy of ADCs against tumor cells. TME creates a barrier to the delivery of ADCs to tumor cells that show resistance to ADCs. This review article aims to highlight the current understanding of the biology of HER2-low breast cancer and its response to ADCs with reference to the tumor microenvironment. - Source: PubMed
Publication date: 2026/03/27
Basem YoussefAta AlamerSherif AbanoubAbdel-Ghany ShaimaaArneth BorrosSabit Hussein